Loading...
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Walls, G. M. Oughton, J. B. Chalmers, A. J. Brown, S. Collinson, F. Forster, M. D. Franks, K. N. Gilbert, A. Hanna, G. G. Hannaway, N.
Walls, G. M.
Oughton, J. B.
Chalmers, A. J.
Brown, S.
Collinson, F.
Forster, M. D.
Franks, K. N.
Gilbert, A.
Hanna, G. G.
Hannaway, N.
Citations
Altmetric:
Abstract
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
Authors
Walls, G. M.
Oughton, J. B.
Chalmers, A. J.
Brown, S.
Collinson, F.
Forster, M. D.
Franks, K. N.
Gilbert, A.
Hanna, G. G.
Hannaway, N.
Harrow, S.
Haswell, T.
Hiley, C. T.
Hinsley, S.
Krebs, Matthew G
Murden, G.
Phillip, R.
Ryan, A. J.
Salem, Ahmed
Sebag-Montefoire, D.
Shaw, P.
Twelves, C. J.
Walker, K.
Young, R. J.
Faivre-Finn, C.
Greystoke, A.
Oughton, J. B.
Chalmers, A. J.
Brown, S.
Collinson, F.
Forster, M. D.
Franks, K. N.
Gilbert, A.
Hanna, G. G.
Hannaway, N.
Harrow, S.
Haswell, T.
Hiley, C. T.
Hinsley, S.
Krebs, Matthew G
Murden, G.
Phillip, R.
Ryan, A. J.
Salem, Ahmed
Sebag-Montefoire, D.
Shaw, P.
Twelves, C. J.
Walker, K.
Young, R. J.
Faivre-Finn, C.
Greystoke, A.
Description
Date
2020
Publisher
Collections
Files
Loading...
FROM CORE
Adobe PDF, 956.01 KB
Keywords
Type
Article
Citation
Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, et al. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol. 2020;25:61-6.